CHICAGO, /PRNewswire/ -- Selagine, Inc., a Spin-Out Company From the University of Illinois at Chicago (UIC), Announced Today that it has Entered into a Research, Development And Sublicense Agreement With Grifols (Nasdaq: GRFS), a Global Leader in Plasma-derived Medicines, For The Development and Commercialization of Immunoglobulin Eye Drops for Dry Eye Disease ...
******************
*************
********
****